专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006101487A1 PRODUCTION AND THERAPEUTIC USES OF TH1-LIKE REGULATORY T CELLS 审中-公开
标题翻译： TH1型调节性T细胞的生产和治疗应用
公开(公告)号：WO2006101487A1
公开(公告)日：2006-09-28
申请号：PCT/US2005/009075
申请日：2005-03-18
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY , UMETSU, Dale , DEKRUYFF, Rosemarie , AKBARI, Omid , STOCK, Philippe
发明人： UMETSU, Dale , DEKRUYFF, Rosemarie , AKBARI, Omid , STOCK, Philippe
IPC分类号： A61K39/02 , A61K45/00 , C12N5/06
CPC分类号： A61K35/15 , A61K2035/122 , A61K2035/124 , A61K2039/515 , C12N5/0636 , C12N5/0637 , C12N5/064 , C12N2502/1107
摘要： A unique CD4 + CD25 + regulatory T cell population develops from naive CD4 + CD25 - T cells during a T H 1 polarized immune response (called T H 1-T R cells). These T H 1-T R cells can be generated by contacting naïve T cells with mature CD8α + dendritic cells (DCs) that have been exposed to a T H 1 polarizing adjuvant and, in some cases, an antigen of interest. The T H 1-T R are identified by their expression of the cytokines IL-10 and IFN-γ, the transcriptional regulators T-bet and FoxP3, and the cell surface molecules CD4, CD25, CD69, CD44 and ICOS.
摘要翻译：在T期间，独特的CD4 + CD25 +调节性T细胞群自幼稚的CD4 + CD4 + T细胞发展 1极化免疫应答（称为T 1 H 1 R T细胞）。可以通过使初始T细胞与已暴露的成熟CD8a +树突状细胞（DC）接触来产生这些T 1 H 1 R T细胞至一种T 1 H偏振性佐剂，在一些情况下为感兴趣的抗原。通过其表达的细胞因子IL-10和IFN-α，转录调节物T-bet和FoxP3以及细胞表面来鉴定T 1 H 1 R T R 分子CD4，CD25，CD69，CD44和ICOS。

2. 发明申请

WO2008100912A1 METHODS FOR ATTENUATING ALLERGEN-INDUCED AIRWAY HYPERREACTIVITY USING CD1D DEPENDENT ANTAGONISTS 审中-公开
标题翻译：使用CD1D依赖性拮抗剂来抑制致敏诱导的航空高效性的方法
公开(公告)号：WO2008100912A1
公开(公告)日：2008-08-21
申请号：PCT/US2008/053688
申请日：2008-02-12
申请人： THE GENERAL HOSPITAL CORPORATION , CHILDREN'S MEDICAL CENTER CORPORATION , WILSON, S. Brian , AKBARI, Omid
发明人： WILSON, S. Brian , AKBARI, Omid
IPC分类号： A61P11/06 , A61P37/08 , A61K31/164 , A61K31/685 , A61K31/739 , A61K31/765
CPC分类号： A61K31/164 , A61K31/685 , A61K31/739 , A61K31/765
摘要： The present invention is directed to a method of inhibiting allergen-induced airway CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Methods of the invention are useful for treatment and prevention of air-way hyperactivity caused by an allergen, and results in the attenuation of CD1d-restricted immune responses, including treatment of hay fever and asthma are due to air-way hyperactivity, and for systemic administration to attenuate ongoing immune responses. Preferably, these compositions are in a form intended for administration via nasal passages or directly inhaled to the air-ways.
摘要翻译：本发明涉及通过施用含有阻断CD1d活化的部分的组合物来抑制变应原诱导的气道CD1d活化的方法。本发明的方法可用于治疗和预防由过敏原引起的气道多动症，并且导致CD1d限制性免疫应答的减弱，包括花粉症和哮喘的治疗是由气道多动症引起的，管理以减轻持续的免疫反应。优选地，这些组合物是用于通过鼻腔给药或直接吸入空气通道的形式。

3. 发明申请

WO2012158556A1 TOLEROGENIC PLASMACYTOID DENDRITIC CELLS CO-EXPRESSING CD8-ALPHA AND CD8-BETA AND METHODS OF INDUCING THE DIFFERENTIATION OF REGULATORY T CELLS USING SAME 审中-公开
标题翻译：共表达CD8-ALPHA和CD8-BET的广谱PLASMACYTOID DENDRITIC细胞和使用它们诱导调节性T细胞分化的方法
公开(公告)号：WO2012158556A1
公开(公告)日：2012-11-22
申请号：PCT/US2012/037628
申请日：2012-05-11
申请人： UNIVERSITY OF SOUTHERN CALIFORNIA , LOMBARDI, Vincent , AKBARI, Omid
发明人： LOMBARDI, Vincent , AKBARI, Omid
IPC分类号： C12N5/0784 , A61K39/00
CPC分类号： C12N5/064 , A61K39/0008 , A61K39/001 , A61K39/39 , A61K2039/5154 , C12N5/0637 , C12N2501/58
摘要： This invention discloses an unexpected discovery that plasmacytoid dendritic cells (pDCs) may be segregated into immunogenic or tolerogenic species based on novel biomarkers discovered herein. Exemplary biomarkers include CD8α + β + , CD8α + β - , CD8α - β - Clq, and IL- 9R. For example, pDCs with CD8α + β + , CD8α + β - are tolerogenic and CD8α - β - is immunogenic. Also disclosed are isolated pDCs, compositions comprising the pDCs, methods for isolating the pDCs, methods for treating immune-hyper-reactivity, such as airway hyper-reactivity, food allergy, asthma, and autoimmune disorders, by using compositions containing tolerogenic antigen presenting cells, preferably pDCs disclosed herein. Also disclosed are methods for identifying tolerogenic antigen presenting cells by using one or more novel biomarkers disclosed herein, including RALDH expression, CD8α, GD8β, Clqa, Clqc, and IL-9R. Also disclosed are methods for inducing Treg cells by using the pDCs disclosed herein.
摘要翻译：本发明公开了一种意想不到的发现，基于本文发现的新型生物标志物，浆细胞样树突状细胞（pDC）可以分离成免疫原性或耐受性物种。示例性生物标志物包括CD8a +ß+，CD8a +ß-，CD8a-β-Clq和IL-9R。例如，具有CD8a +ß+，CD8a +β的pDC具有致敏性，CD8a-β是免疫原性的。还公开了分离的pDC，包含pDC的组合物，分离pDC的方法，用于治疗免疫超反应性的方法，例如气道高反应性，食物过敏，哮喘和自身免疫性疾病，通过使用含有耐受性抗原呈递细胞的组合物，优选在此公开的pDC。还公开了通过使用本文公开的一种或多种新型生物标志物来鉴定耐受性抗原呈递细胞的方法，包括RALDH表达，CD8a，GD8β，Clqa，Clqc和IL-9R。还公开了通过使用本文公开的pDC诱导Treg细胞的方法。

4. 发明申请

WO2013019980A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ASSOCIATED DISORDERS 审中-公开
标题翻译：用于治疗哮喘和相关疾病的组合物和方法
公开(公告)号：WO2013019980A1
公开(公告)日：2013-02-07
申请号：PCT/US2012/049381
申请日：2012-08-02
申请人： UNIVERSITY OF SOUTHERN CALIFORNIA , AKBARI, Omid
发明人： AKBARI, Omid
IPC分类号： A61K38/08 , A61K38/10 , A61K38/16 , A61K31/135 , A61K31/13 , A61P11/06 , A61P11/00
CPC分类号： A61K31/55 , A61K31/138 , A61K31/277 , A61K31/4168 , A61K31/506 , A61K31/513 , A61K38/08 , A61K38/10 , A61K38/1709 , C07K14/4703 , G01N33/5091 , G01N2800/24
摘要： This disclosure provides methods for treating asthma or an associated disorder in a patient in need thereof, by administering to the patient an effective amount of an autophagy inducing agent, thereby treating the asthma or the associated disorder. Disorders that can be treated include, allergic asthma, chronic obstructive pulmonary disease, lung inflammation, respiratory tolerance and a lung infection or disorder.
摘要翻译：本公开提供了通过向患者施用有效量的自噬诱导剂，从而治疗哮喘或相关疾病，来治疗有需要的患者中的哮喘或相关病症的方法。可治疗的疾病包括过敏性哮喘，慢性阻塞性肺疾病，肺部炎症，呼吸道耐受和肺部感染或疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式